The news of JP Morgan maintaining an Overweight rating and raising the price target for Neurocrine Biosciences is likely to have a positive impact on the company's stock in the short term. This is because such an announcement from a reputable financial institution like JP Morgan can boost investor confidence in the company, potentially leading to an increase in the stock price.